Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18230734 | 0.98 | CYP4F2 (0.54) | CYP4F2CYP4A11TBXAS1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL27552763 | 0.98 | CYP4F2 (0.54) | CYP4F2CYP4A11TBXAS1ALDH1A1TDP1 | |
| SCHEMBL10622938 | 0.91 | TBXAS1 (0.57) | TBXAS1ALDH1A1TDP1L3MBTL1TSHR | |
| SCHEMBL11062768 | 0.90 | TBXAS1 (0.66) | CYP4F2CYP4A11TBXAS1ALDH1A1TDP1 | |
| SCHEMBL5962751 | 0.90 | TBXAS1 (0.64) | CYP4F2CYP4A11TBXAS1ALDH1A1TDP1 | |
| SCHEMBL30178297 | 0.90 | TBXAS1 (0.64) | CYP4F2CYP4A11TBXAS1ALDH1A1TDP1 | |
| SCHEMBL8304942 | 0.89 | TBXAS1 (0.54) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL5642735 | 0.88 | ALDH1A1 (0.50) | TBXAS1ALDH1A1TDP1L3MBTL1TSHR | |
| SCHEMBL18230749 | 0.88 | ALDH1A1 (0.46) | CYP4F2CYP4A11TBXAS1ALDH1A1TSHR | |
| SCHEMBL12999584 | 0.87 | POLB (0.56) | ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0070185-A1 | Preparation of lower alkyl 2-formyl-3-(6-methyl-3-pyridinyl)-propionates | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | claimed |
| EP-4374698-B1 | PYRIDINIUM ESTERS | PROCTER & GAMBLE (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240217932-A1 | PYRIDIUM ESTERS | THE PROCTER AND GAMBLE COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4374698-A1 | PYRIDINIUM ESTERS | The Procter & Gamble Company (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-1703908-A4 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| EP-0206294-A1 | Alkyl esters of 3-hydroxy-3-(2-methyl-5-pyridyl)-propionic acid | LONZA AG (CH) | 1986-12-30 | — | — | EP | disclosed |
| US-4539207-A | Pyrimidine compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-09-03 | — | — | US | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217932-A1 | PYRIDIUM ESTERS | C5, CBR3, CHRM1 | CYP4F2 70/4885CYP4A11 65/4885TBXAS1 1042/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | CYP4F2 407/4885CYP4A11 51/4885TBXAS1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.